PrintThe Burrill Report
The Burrill Report (August 27, 2012): Feeling Love for Orphans (.MP3,10.22 Mb)
Orphan drugs, which are developed to treat rare diseases, are being recognized for their big market potential. A new study from Thomson Reuters finds that not only is orphan drug growth outpacing the growth of non-orphan drugs, but that the lifetime revenue potential for these drugs rivals the lifetime revenue potential for drugs targeting more common health conditions. We spoke to Kiran Meekings, life sciences consultant at Thomson Reuters, about the new report, what’s driving the industry’s interest in orphan drugs, and why they represent promising opportunities for growth.
August 24, 2012
http://www.burrillreport.com/article-feeling_love_for_orphans.html
BUSINESS DEVELOPMENT
Feeling Love for Orphans
Podcast: August 27, 2012[Please login to post comments]
- The November 2012 Issue of
The Burrill Report
Read More - Russia’s PM Backs Smoking Ban
Government pursues broad measures to improve Russians’ health. Read More - Abbott Stumbles Ahead of Spinoff
Partner Reata halts trial of late-stage drug, expected to be a potential blockbuster. Read More - FDA Advisors Back Genzyme-Isis Cholesterol Drug
Isis stands to claim $25 million milestone if U.S. regulator approves new drug. Read More - Multivitamins Reduce Men’s Cancer Risk
Long-term study shows value of supplements. Read More - Samsung Halts Trials of Biosimilar
Company cites 'internal reasons' for action, says report. Read More - Six Biotechs Price Secondary Offerings
Companies take advantage of improved public markets and their own progress to raise money. Read More - AiCuris Strikes $571 Million Deal with Merck
Bayer spin-off gets $144 million upfront for its anti-viral program. Read More - Three Early-Stage Biotechs Launch
Creative business models, innovative compounds, and proven management teams attract capital. Read More - Harnessing Data to Improve Care
Podcast: October 22, 2012 Read More
.gif)
